Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

2.1.1.6: catechol O-methyltransferase

This is an abbreviated version!
For detailed information about catechol O-methyltransferase, go to the full flat file.

Word Map on EC 2.1.1.6

Reaction

S-adenosyl-L-methionine
+
a catechol
=
S-adenosyl-L-homocysteine
 +
a guaiacol

Synonyms

catechol methyltransferase, catechol-O-methyl transferase, catechol-O-methyl transferase, membrane bound, catechol-O-methyl transferase, soluble, catechol-O-methyltransferase, catechol-O-transferase, catecholamine O-methyltransferase, COMT, COMT I, COMT II, COMT-mb, COMT-s, COMT1, COMT2, CTOMT1, L-COMT, MB-COMT, methyltransferase, catechol, S-COMT, SCOMT

ECTree

     2 Transferases
         2.1 Transferring one-carbon groups
             2.1.1 Methyltransferases
                2.1.1.6 catechol O-methyltransferase

Inhibitors

Inhibitors on EC 2.1.1.6 - catechol O-methyltransferase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(-)-epicatechin-3-gallate
-
IC50: 0.0002 mM with 2-hydroxyestradiol as substrate, IC50: 0.0003 mM with 4-hydroxyestradiol as substrate
(-)-epigallocatechin
-
IC50: 0.044 mM with 2-hydroxyestradiol as substrate, IC50: 0.05 nM with 4-hydroxyestradiol as substrate
(-)-epigallocatechin gallate
-
potent inhibitor with epigallocatechin or 3,4-dihydroxy-L-Phe as substrates
(-)-epigallocatechin gallate-4''-O-glucuronide
-
with epigallocatechin or 3,4-dihydroxy-L-Phe as substrates
(-)-epigallocatechin gallate-7-O-glucuronide
-
with epigallocatechin or 3,4-dihydroxy-L-Phe as substrates
(-)-epigallocatechin-3-gallate
(-)-epigallocatechin-3-gallate-3''-O-glucuronide
-
IC50: 0.002 mM with 2-hydroxyestradiol as substrate, IC50: 0.0025 mM with 4-hydroxyestradiol as substrate
(-)-epigallocatechin-3-gallate-3'-O-glucuronide
-
IC50: 0.0018 mM with 2-hydroxyestradiol as substrate, IC50: 0.0023 mM with 4-hydroxyestradiol as substrate
(-)-epigallocatechin-3-gallate-4''-O-glucuronide
-
IC50: 0.0025 mM with 2-hydroxyestradiol as substrate, IC50: 0.004 mM with 4-hydroxyestradiol as substrate
(-)-epigallocatechin-3-gallate-7-O-glucuronide
-
IC50: 600 nM with 2-hydroxyestradiol as substrate, IC50: 800 nM with 4-hydroxyestradiol as substrate
(-)-epigallocatechin-3-O-gallate
(-)epicatechin
-
IC50: 0.06 mM with 2-hydroxyestradiol as substrate, IC50: 0.08 mM with 4-hydroxyestradiol as substrate
(-)epicatechin gallate3,5-dinitrocatechol
-
with epigallocatechin or 3,4-dihydroxy-L-Phe as substrates
(2-amino-3-methylbutanoyloxy)methyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
(2E)-4,7-anhydro-1,2,3-trideoxy-1-(2,3-dihydroxy-5-nitrobenzamido)-L-ribo-hept-2-enitol
-
-
(2R,3R)-5,7-bis(acetyloxy)-2-[3,4,5-tris(acetyloxy)phenyl]-3,4-dihydro-2H-chromen-3-yl 3,4-bis(acetyloxy)-5-(2-oxopropyl)benzoate
-
-
(2R,3S)-1,2,3,4-tetrahydronaphthalene-2,3-diyl bis(3,4,5-trihydroxybenzoate)
-
-
(2R,3S)-1,2,3,4-tetrahydronaphthalene-2,3-diyl bis(3,5-dihydroxybenzoate)
-
-
(2R,3S)-1,2,3,4-tetrahydronaphthalene-2,3-diyl bis[3,4,5-tris(acetyloxy)benzoate]
-
-
(2R,3S)-1,2,3,4-tetrahydronaphthalene-2,3-diyl bis[3,5-bis(acetyloxy)benzoate]
-
-
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
1,2-dihydroxy-4-[2-(methylamino)butyl]benzene
-
uncompetitive inhibitor of the sCOMT isoform
1-(4-butylphenyl)-5-hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one
-
1-(butyryloxy)ethyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
1-(isobutyryloxy)ethyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
1-([1,1'-biphenyl]-3-yl)-3-hydroxypyridin-4(1H)-one
-
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-(1-hydroxy-2-methylpropyl)pyridin-4(1H)-one
-
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-(1-hydroxybutyl)pyridin-4(1H)-one
-
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-(1-hydroxyethyl)pyridin-4(1H)-one
-
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one
-
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-methylpyridin-4(1H)-one
-
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-phenylpyridin-4(1H)-one
-
1-([1,1'-biphenyl]-3-yl)-5-hydroxy-2-[hydroxy(phenyl)methyl]pyridin-4(1H)-one
-
1-([1,1'-biphenyl]-4-yl)-5-hydroxy-2-(hydroxymethyl)pyridin-4(1H)-one
-
1-Carboxysalsoline
-
i.e. 1-carboxy-1-methyl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline, competitive inhibition of 3,4-dihydroxybenzoic acid methylation
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-4-(trifluoromethyl)-1H-imidazole
-
-
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]benzo[d]imidazole
-
-
1-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]pyridin-4(1H)-one
-
-
1-[1-(2-chlorobenzyl)-1H-benzimidazol-4-yl]-3-hydroxypyridin-4(1H)-one
1-[3,4-dihydroxy-5-nitrophenyl]-2-phenyl-ethanone
-
-
1-[3-(5-chloro-1H-pyrrolo[2,3-b]pyridin-4-yl)phenyl]-5-hydroxy-2-(1-hydroxyethyl)pyridin-4(1H)-one
13-hydroxy-36-(trifluoromethyl)-14H-[11,22:24,32-terpyridin]-14-one
-
2-Hydroxyestradiol-17beta 3-methyl ether
-
product inhibition
2-hydroxyoestrogen
-
-
2-Iodosobenzoic acid
-
-
2-methoxyestradiol-17beta
-
product inhibition
3,4,5-trihydroxypyrogallol
-
liver homogenate, 0.03 mM inhibitor: 0.8% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
3,4-dihydroxymethamphetamine
-
uncompetitive inhibitor of the sCOMT isoform
3,5-dinitrocatechol
3-Carboxysalsolinol
-
-
3-chloro-5,6-dihydroxy-7-nitro-1-benzothiophene-2-carboxylic acid
-
-
3-fluoro-4-[1-[4-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]benzene-1,2-diol
-
liver homogenate, 0.03 mM inhibitor: 32.3% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
3-hydroxy-4'-phenyl-4H-[1,2'-bipyridin]-4-one
potent inhibitor with sufficient in vivo exposure to significantly affect the dopamine metabolites homovanillic acid and dihydroxyphenylacetic acid
3-nitro-5-(1-p-tolyl-1H-pyrazol-5-yl)benzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitor: 0% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
3-nitro-5-(1-phenyl-1H-pyrazol-5-yl)benzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitor: 0% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
3-nitro-5-(1H-pyrazol-5-yl)benzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitor: 0% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
4''-O-methyl epigallocatechin gallate
-
potent inhibitor with epigallocatechin or 3,4-dihydroxy-L-Phe as substrates
4',3'',4''-tri-O-methyl epigallocatechin gallate
-
substrate: epigallocatechin
4',4''-di-O-methyl epigallocatechin gallate
-
potent inhibitor with epigallocatechin or 3,4-dihydroxy-L-Phe as substrates
4'-(1-benzyl-1H-pyrazol-4-yl)-3-hydroxy-4H-[1,2'-bipyridin]-4-one
-
4'-(3,4-dichlorophenyl)-3-hydroxy-4H-[1,2'-bipyridin]-4-one
-
4'-4''-di-O-methyl-epigallocatechin-3-gallate
-
IC50: 0.00015 mM with 2-hydroxyestradiol or 4-hydroxyestradiol as substrate, competitive with respect S-adenyosylmethionine, noncompetitive with respect to catechol
4'-fluoro-3-hydroxy-5'-phenyl-4H-[1,3'-bipyridin]-4-one
-
4'-fluoro-4,5-dihydroxy-biphenyl-3-carboxylic acid [(E)-3-[(2S,4R,5R)-4-hydroxy-5-(6-methyl-purin-9-yl)-tetrahydro-furan-2-yl]-allyl]-amide
-
4'-fluoro-4,5-dihydroxy-biphenyl-3-carboxylic acid [(E)-3-[(2S,4R,5R)-4-hydroxy-5-(6-methylamino-purin-9-yl)-tetrahydro-furan-2-yl]-allyl]-amide
-
4'-O-methyl-(-)-epigallocatechin
-
IC50: 0.032 mM with 2-hydroxyestradiol as substrate, IC50: 0.04 mM with 4-hydroxyestradiol as substrate
4'-O-methyl-epigallocatechin-3-gallate
-
IC50: 0.0001 mM with 2-hydroxyestradiol or 4-hydroxyestradiol as substrate
4-(1-phenyl-1H-pyrazol-5-yl)benzene-1,2,3-triol
-
liver homogenate, 0.03 mM inhibitor: 26.8% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
4-(5-(3,4-dihydroxy-5-nitrophenyl)-1H-pyrazol-1-yl)benzonitrile
-
liver homogenate, 0.003 mM inhibitor: 0.3% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
4-(tert-octyl)phenol
-
causes significant inhibition of enzyme activity
4-hydroxyequilenin
-
inhibits its own methylation by COMT at higher concentrations in the presence of the reducing agent dithiothreitol, irreversible inhibitor, the inhibitor causes formation of intermolecular disulfide bonds, cys33 in recombinant human soluble COMT is the residue most likely modified by the inhibitor
4-nitrocatechol
-
-
4-phenyl-7,8-dihydroxycoumarin
-
4-[1-(4-methylphenyl)-1H-pyrazol-5-yl]benzene-1,2-diol
-
liver homogenate, 0.03 mM inhibitor: 41.2% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
4-[4-(4-chlorophenyl)-5-methyl-1H-pyrazol-3-yl]benzene-1,2,3-triol
-
liver homogenate, 0.003 mM inhibitor: 15.6% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
5-(1-methyl-1H-pyrazol-5-yl)-3-nitrobenzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitor: 1.1% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
5-(cyclopentylsulfonyl)-7-fluoroquinolin-8-ol
compound displays good pharmacokinetics in rats. pIC50 value 8.7 for membrane-bound form, 5.6 for soluble form
5-hydroxy-1-[3-(isoquinolin-4-yl)phenyl]-2-(2,2,2-trifluoro-1-hydroxyethyl)pyridin-4(1H)-one
5-hydroxy-2-(thiophen-2-yl)pyrimidin-4(1H)-one
-
5-Substituted 3-hydroxy-4-methoxybenzaldehydes
-
-
5-Substituted 3-hydroxy-4-methoxybenzoic acids
-
-
5-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-5H-imidazo[4,5-c]pyridine
-
-
5-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]-5H-pyrrolo[3,2-c]pyridine
-
-
5-[1-(3-chlorophenyl)-1H-pyrazol-5-yl]-2,3-dihydroxybenzoic acid
-
liver homogenate, 0.03 mM inhibitor: 24.1% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
5-[1-(3-chlorophenyl)-1H-pyrazol-5-yl]-3-nitrobenzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitor: 0% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
5-[1-(3-chlorophenyl)-4-phenyl-1H-pyrazol-5-yl]-3-nitrobenzene-1,2-diol
-
liver homogenate, 0.003 mM inhibitor: 68.6% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
6-methyl-9-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]purine
-
-
7-chloro-5-((4-fluorophenyl)sulfonyl)quinolin-8-ol
compound exhibits very low clearance and long half-life in rat pharmacokinetics studies. pIC50 value 6.7 for membrane-bound form, below 5 for soluble form
7-chloro-5-(cyclopentylsulfonyl)quinolin-8-ol
compound exhibits very low clearance and long half-life in rat pharmacokinetics studies. pIC50 value 7.7 for membrane-bound form, below 5 for soluble form
7-chloro-5-(pyrrolidin-1-ylsulfonyl)quinolin-8-ol
compound exhibits very low clearance and long half-life in rat pharmacokinetics studies . pIC50 value 8.0 for membrane-bound form, 5.5 for soluble form
7-fluoro-5-(pyrrolidin-1-ylsulfonyl)quinolin-8-ol
compound displays good pharmacokinetics in rats. pIC50 value 8.4 for membrane-bound form, 5.8 for soluble form
8-O-methyldaphnetin
0.1 mM, about 20% residual activity. 8-O-methyldaphnetin has no effect on Km but decreases Vmax
9-hydroxypyrido[2,1-c][1,4]benzothiazin-8(6H)-one
-
9-[(5E)-3,5,6,7-tetradeoxy-3-fluoro-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-xylo-hept-5-enofuranosyl]-N6-methyladenine
-
9-[(5E)-3,5,6,7-tetradeoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-3-methyl-beta-D-xylo-hept-5-enofuranosyl]-N6-propyladenine
-
9-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]purine
-
-
amino group reagents
-
-
-
Analogs of S-adenosyl-L-homocysteine
-
overview: inhibition of the liver, heart and brain enzyme
ascorbic acid
-
-
benzyl butyl phthalate
-
causes significant inhibition of enzyme activity
benzyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
beta-thujaplicin
-
70-100% inhibition at 0.2 mM
butyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
butyryloxymethyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
caffeic acid
caffeic acid phenethyl ester
-
COMT from liver, using 2-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37°C; COMT from liver, using 4-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37°C
catechin
catechol
-
-
CGP 28014
-
-
chlorogenic acid
-
COMT from liver, using 2-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37°C; COMT from liver, using 4-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37°C; COMT from placenta, using 2-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37°C; COMT from placenta, using 4-hydroxyestradiol as substrate, in Tris-HCl buffer (10 mM, pH 7.4), at 37°C
chrysin
-
slight inhibition at 0.3 mM
Cistus parviflorus leaf extract
-
mixed type inhibition
-
daidzein
-
soy isoflavones at hormonally active concentrations cause a significant reduction of both COMT mRNA levels and COMT activity as well as of the methylation of 4-hydroxyestradiol
daphnetin
0.1 mM, about 10% residual activity
dibutyl phthalate
-
causes significant inhibition of enzyme activity
dihydromyricetin
-
competitive
diisononyl phthalate
-
causes significant inhibition of enzyme activity
dioctyl phthalate
-
causes significant inhibition of enzyme activity
dobutamine
-
competitive to dopamine
dopamine
-
competitive to dobutamine
entacapone
epicatechin
epigallocatechin
epigallocatechin-3-gallate
-
inhibition in vitro. Supplementation with a high dose does not impair the activity of COMT
Fe3+
quantum mechanical/molecular mechanical dynamics study
fisetin
flavone
-
IC50: 0.00549 mM
flavonoids
-
overview: relationship between structure and ability to inhibit
gallic acid
Gallic acid methylester
-
-
genistein
Hg2+
-
complete inhibition at 1 mM
high ionic strength
-
-
-
homocysteine
-
-
iodoacetamide
-
slight
iodoacetic acid
isobutyryloxymethyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
isopropyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
L-ascorbic acid
L-Dopa
lactoferrin
bovine lactoferrin binds to and inhibits COMT using its N-terminal region. A fragment of the lactoferrin N-terminal residues 6-50, with two pairs of disulfide bonds, shows higher inhibitory activity than intact lactoferrin. Lactoferrin does not compete with S-adenosylmethionine. COMT activity in the cell extracts form Caco-2 and HepG2 cells is inhibited by lactoferrin and the N-terminal fragment
-
methyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
myricetin
-
competitive
Myricitrin
-
competitive
N-(2-[2-[(2R,3S,4R,5R)-5-(6-amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-yl]-ethoxy]-ethyl)-2,3-dihydroxy-5-nitro-benzamide
-
IC50: 0.002 mM
N-(3,4-Dihydroxyphenyl)maleimide
-
irreversible
N-(3,4-Dihydroxyphenyl)succinimide
-
reversible
N-ethyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-imidazole-4-carboxamide
-
-
N-ethyl-3,4-dihydroxyamphetamine
-
uncompetitive inhibitor of the sCOMT isoform
N-ethylmaleimide
N-methyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-1,2,4-triazole-3-carboxamide
-
-
N-methyl-1-[(5E)-5,6,7-trideoxy-7-[5-(4-fluorophenyl)-2,3-dihydroxybenzamido]-beta-D-ribo-hept-5-enofuranosyl]-1H-imidazole-4-carboxamide
-
-
N-[(2E)-3-[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(methylamino)-9H-purin-9-yl]tetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,4R,5R)-3,4-dihydroxy-5-[6-(propylamino)-9H-purin-9-yl]tetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
N-[(2E)-3-[(2R,3S,4R,5R)-5-(6-ethyl-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,4R,5R)-5-[6-(cyclopropylamino)-9H-purin-9-yl]-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,4R,5R)-5-[6-(ethylamino)-9H-purin-9-yl]-3,4-dihydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-4'-fluoro-4,5-dihydroxybiphenyl-3-carboxamide
-
N-[(2E)-3-[(2R,3S,5R)-5-(6-amino-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
-
N-[(2E)-3-[(2S,4R,5R)-5-(6-amino-9H-purin-9-yl)-4-hydroxytetrahydrofuran-2-yl]prop-2-en-1-yl]-2,3-dihydroxy-5-nitrobenzamide
-
N-[(E)-4-[(2R,3S,4R,5R)-5-(6-Amino-purin-9-yl)-3,4-dihydroxy-tetrahydro-furan-2-yl]-but-2-enyl]-2,3-dihydroxy-5-nitro-benzamide
-
IC50: 9 nM
N-[2-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]ethyl]-2,3-dihydroxy-5-nitrobenzene-1-carboxamide
-
IC50: 60 nM
N-[3-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]propyl]2,3-dihydroxy-5-nitrobenzene-1-carboxamide
-
IC50: 200 nM
N-[4-[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl]butyl]-2,3-dihydroxy-5-nitrobenzene-1-carboxamide
-
IC50: 0.005 mM
N-[[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl]-2,3-dihydroxy-5-nitrobenzene-1-carboxamide
-
IC50: 0.09 mM, very potent bisubstrate inhibitor
N6-methyl-9-[(5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-beta-D-ribo-hept-5-enofuranosyl]adenine
-
-
nebicapone
-
-
nitecapone
-
-
nordihydroguaiaretic acid
-
-
norepinephrine
-
0.01 mM, 41% inhibition of 2-hydroxyestradiol methylation
OR-462
-
disubstituted catechol
OR486
-
depressed COMT activity results in enhanced mechanical and thermal pain sensitivity
p-chloromercuribenzoate
p-hydroxymercuribenzoate
-
70-100% inhibition at 0.2 mM
Peganum harmala seed extract
-
mixed type inhibition
-
Phenolic compounds
-
-
-
Polyphenolic compounds
-
-
-
propyl-3-chloro-5,6-dihydroxy-7-nitrobenzo[b]thiophene-2-carboxylate
-
-
purpurogallin
purpurogallin carboxylic acid
-
-
pyridin-4-yl (5E)-5,6,7-trideoxy-7-(2,3-dihydroxy-5-nitrobenzamido)-1-thio-beta-D-ribo-hept-5-enofuranoside
-
-
pyrogallol
quercetin
Ro 41-0960
RO-4-4602
-
competitive
Ro41-0960
S-adenosyl-L-homocysteine
S-adenosyl-L-methionine
-
-
Salsolidine
salvianolic acid B
-
weak inhibitor. In vivo, a single intravenous dose of salvianolic acid B decreases the plasma concentration of 3-O-methyldopa, with no obvious effect on the pharmacokinetics of L-dopa
theaflavin-3,3'-digallate
-
decreased Vmax and increased Km-value
tolcapone
Triton X-100
-
-
tropolone
U-0521
Vitex agnus-cactus leaf extract
-
mixed type inhibition
-
[5-(3,4-dihydroxy-5-nitrophenyl)-4-phenyl-1H-pyrazol-1-yl](4-methylphenyl)methanone
-
liver homogenate, 0.003 mM inhibitor: 2.8% metanephrine formed relative to the control in absence of inhibitor (5 min reaction time), pH 7.8, 37°C
additional information
-